Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Other Events

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Other Events

Story continues below

Item8.01 Other Events.

On March 23, 2017, Bellicum Pharmaceuticals, Inc. (Bellicum)
entered into an Underwriting Agreement (the Underwriting
Agreement) with Citigroup Global Markets Inc. and Jefferies LLC,
as representatives of the several underwriters (the
Underwriters), relating to the offering, issuance and sale (the
Offering) of 5,000,000 shares of Bellicums common stock, $0.01
par value per share (the Common Stock), at a price to the public
of $12.00 per share, which Bellicum estimates will result in
approximately $56.0 million of net proceeds to Bellicum after
deducting the underwriting discounts and commissions and
estimated offering expenses. The Offering is expected to close on
or about March 29, 2017, subject to the satisfaction of customary
closing conditions. In addition, the Underwriters have a
30-day option to
purchase up to an additional 750,000 shares of Common Stock. All
of the shares in the Offering are being sold by Bellicum.

The Offering is
being made to Bellicums effective shelf registration statement on
Form S-3 (Registration No.333-209012) previously filed with the
Securities and Exchange Commission, as supplemented by a
preliminary prospectus supplement dated March 22, 2017 and a
final prospectus supplement dated March 23, 2017.

The Underwriting
Agreement contains customary representations, warranties and
agreements by Bellicum, conditions to closing, indemnification
obligations of Bellicum and the Underwriters, including for
liabilities under the Securities Act of 1933, as amended, other
obligations of the parties and termination provisions. The
representations, warranties and covenants contained in the
Underwriting Agreement were made only for purposes of such
agreement and as of specific dates, were solely for the benefit
of the parties to such agreement and may be subject to
limitations agreed upon by the contracting parties.

The Underwriting
Agreement is filed as Exhibit 1.1 hereto and is incorporated
herein by reference. The foregoing description of the terms of
the Underwriting Agreement is qualified in its entirety by
reference to such exhibit.

A copy of the
opinion of Cooley LLP relating to the legality of the issuance
and sale of the shares in the Offering is attached as Exhibit 5.1
hereto.

Item9.01
Financial Statements and Exhibits.

(d)
Exhibits.

The following
exhibits are filed as part of this Current Report:

1.1 Underwriting Agreement, dated March 23, 2017, by and among
Bellicum Pharmaceuticals, Inc., Citigroup Global Markets Inc.
and Jefferies LLC, as representatives for the several
underwriters.
5.1 Opinion of Cooley LLP.
23.1 Consent of Cooley LLP (included in Exhibit 5.1).


About Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company’s CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Recent Trading Information

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) closed its last trading session down -0.86 at 12.04 with 1,108,798 shares trading hands.

An ad to help with our costs